Compare Merck & Co., Inc. (MRK) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vistra Corp — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Vistra Corp trades at $162.23 (market cap $53.27B). The key difference: Merck & Co., Inc. is far larger — about 5.8× Vistra Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | VST | |
|---|---|---|
Market Cap | $307.25B | $53.27B |
Sector | Health | Technology |
52-Week High | $129.52 | $217.92 |
52-Week Low | $77.60 | $134.71 |
Enterprise Value | $350.66B | $75.03B |
Dividend Yield | 2.73% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Vistra Corp (VST) trades at $157.99, up 1.64% with strong institutional support and bullish technical signals. The stock shows robust fundamentals with 74.92% ROE and 11.52% net margin, though recent earnings were mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Analyst consensus remains overwhelmingly positive with 91% buy ratings and a $253 price target, representing 60% upside potential. Recent news highlights Vistra's positioning in the AI power infrastructure boom and long-term power purchase agreements with major tech companies.
Vistra presents significant growth potential driven by AI infrastructure demand and nuclear energy expansion, but faces risks from power price volatility and high debt levels. The company's diversified utility operations and strategic PPAs provide revenue stability, while technical indicators suggest continued upward momentum with key resistance at $159-$162. Investors should weigh the strong analyst support against execution risks in capital-intensive energy projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
